Page 149 - CW E-Magazine (25-2-2025)

Top Stories Pharmaceuticals

SETTING NEW STANDARDS TRADE TRENDS

Elgi unveils new high performance air compressors Pharma exports to beat FY25 target; API values

Elgi Equipments Ltd., one of the with global sustainability goals. Its under pressure
world’s leading air-compressor manu- implementation in industrial plants
facturers, has announced the introduc- represents a shift towards greener, India’s pharmaceutical industry is COVID-19 pandemic. However, the experts predict the total for the year may
tion of its pioneering compressed air more cost-effective manufacturing witnessing strong growth in exports, Ayush and herbal segment has displayed exceed last year’s fi gure of $5.5-bn.
stabilization technology. Designed to processes,” said Dr. Jairam Varadaraj, with the sector poised to exceed its FY25 resilience, growing 13%. Africa remains another key market
revolutionize the way compressors Managing Director, Elgi Equipments. target ahead of time.Government data US – still the key market for Indian pharmaceutical exports, but
operate in plants with dynamic air de- indicates that by October last year, 99% The US still remains a crucial mar- has shown signs of contraction. The
mand, the STABILISOR system aims According to Dr. Venu Madhav, of the export target had been achieved, ket for Indian pharmaceutical exports. region recorded $4-bn in exports last
to address the longstanding challenges Director Technology, Elgi Equipments, raising expectations that the fi nal fi gures Experts estimate that North America year, but fi gures have dipped by 3% in
of unstable compressor performance, the system utilizes precision-engineered will surpass initial projections. has already recorded $6.2-bn in exports, recent months.Analysts believe with
ineffi ciency, and excessive wear caused progressive and on-off valves to recir- According to data from the Directo- and if the current trend continues, it political stability returning in some
by frequent load/unload cycles. employs a fi rst of its kind ‘Recirculate culate excess capacity within the sys- rate General of Commercial Intelligence may reach $10-bn by March this year. regions, market conditions may improve.
and Recover’ principle, seamlessly tem. “This system leverages stabiliza- and Statistics (DGCIS), drug formula- Despite issues such as back orders and The long-term potential remains strong,
In industrial settings, the gap bet- aligning compressor capacity with tion zones and low-pressure recovery tions and biological products continue drug shortages, the sector has grown by and experts predict exports to Africa
ween compressor capacity and plant plant air demand through controlled techniques to balance airfl ow demands to dominate pharmaceutical exports, 17%. Analysts believe that without these could surpass $10-bn in the future.
air demand is inherently dynamic. This recirculation and recovery tech- dynamically, minimize energy losses accounting for 75% of the total.This seg- challenges, growth could have been as
variability leads to frequent cut-in and niques. By stabilizing airfl ows within by targeting pressure points with minimal ment has grown 11% in FY25, further high as 25%. Russia has emerged as a potential
cut-out operations, which destabilize the system, the STABILISOR system differences all while maximizing over- reinforcing India’s position as a global game-changer for the industry. The on-
the compressor and impair critical fl ow minimizes load/unload cycles, en- all system reliability.” pharmaceutical hub. While exports In Europe, the export performance going geopolitical tensions have led to
and kinematic components. Traditional suring extended equipment lifespan, of Active Pharmaceutical Ingredients has been mixed, and overall growth signifi cant drug shortages in that coun-
solutions, such as increasing reservoir optimizes energy use, achieving up The STABILISOR system will be (API) have recorded growth in volume, has remained stagnant, primarily due to try, creating a substantial opportunity
volume, altering cut-in/cut-out pres- to 15% energy savings in typical available in India and across the globe, their overall value has declined. Experts weaker demand in the Netherlands and for Indian pharmaceutical companies.
sures, or adding variable frequency applications, while reducing system in 2025, in two versions: a Light Ver- attribute this to a drop in prices of APIs Belgium. However, the UK recorded Analysts estimate exports to Russia
drives (VFDs), often fall short, intro- ineffi ciencies, maintaining superior sion, designed for fi eld fi tment, energy and intermediates from China. an impressive 22% increase, while could grow by 15%, as many global sup-
ducing new inefficiencies or higher performance across varying demand savings and enhanced reliability; and a Germany has seen a moderate 6% growth pliers are hesitant to send consignments
operational costs. patterns. With its energy-effi cient Heavy Version, factory-fi tted for supe- The vaccine sector has also faced despite facing economic recession. due to the current confl ict. This could
design and potential to reduce wear- rior energy savings and comprehensive challenges, showing a 9% decline due Overall, the European market logged give Indian fi rms an edge in fi lling the
“The STABILISOR system and-tear, the STABILISOR aligns stability. to reduced demand after the end of the $3.2-bn in exports by October, and supply gap.

BIOFUELS MARKET TRENDS
BPCL & NSI (Kanpur) to develop sweet sorghum Indian pharma market registers over 8% growth in Jan 25

The Indian pharmaceutical market turnover of over Rs. 2.23-trillion in IPM. constitute around 37% of IPM, showed
as feedstock for bioethanol (IPM) grew by 8.7% in January The MAT of cardiac, gastrointestinal, volume growth at 11.2%, 10%, and
this year, with major therapies and anti-infectives, which together 5.8%, respectively.
Bharat Petroleum Corporation Ltd. BPCL has pledged Rs. 5-crore to sup- showing positive value growth,
(BPCL) has entered into Memoran- port research and development initiatives according to market research firm, INTERNATIONAL RECOGNITION
dum of Understanding (MoU) with the within this partnership. The funding will Pharmarack. Dr.Navin Saxena conferred Russian honours
National Sugar Institute (NSI) in Kanpur aim to optimise sweet sorghum yields,
to collaboratively develop sweet enhance agricultural practices, and create Among them, the cardiac, anti-dia- RusanPharma Ltd., a global leader Moscow’s People’s Friendship Uni-
sorghum as an eco-friendly feedstock effi cient juice extraction and fermenta- betic, and gastrointestinal therapies saw in pharmaceutical innovation, has versity.
for bioethanol production. This strate- tion methods to boost ethanol produc- high value growth of 10.9%, 10.2%, and announced that its Chairman,
gic alliance supports India’s Ethanol tion. Additionally, this collaboration will 6.9%, respectively. Growth in the mov- Dr.Navin Saxena, has been honoured These honours recognise Dr.Saxena’s
Blended Petrol (EBP) Programme and examine the use of leftover biomass for ing annual turnover (MAT, which is the with two of Russia’s most distin- exceptional contribution to science,
aligns with the government’s objec- compressed biogas (CBG) and other previous 12 months’ turnover) for IPM guished accolades: ‘The Order of medicine, pharmaceutical innova-
tives to promote biofuels and diminish value-added applications, promoting a between February 2024 and January Friendship’ by the Russian Federa- tions including cross-cultural collabo-
reliance on fossil fuels. comprehensive approach to bioenergy use. 2025 stood at 8.3%, leading to a total tion & the ‘Memorial Medal’ from ration over his 40-year career.

148 Chemical Weekly February 25, 2025 Chemical Weekly February 25, 2025 149

Contents Index to Advertisers Index to Products Advertised